A major frontier in medical genetics is the definition of the molecular basis of multifactorial diseases. This is especially relevant in the field of clinical psychiatry where the majority of common disorders display complex inheritance patterns, and are further influenced by environmental interactions. New technologies are needed to help address the pressing needs for discovering and deciphering the nature of such disease-associated genes. One such technology which has emerged within the past 3 years involves hybridization-based nucleic acid array (DNA chip) analysis. This technology has the potential to have a lasting impact on diverse genomic-based applications such as large-scale gene mapping studies, mutational analysis, and global expression level monitoring of all human genes. In this review we will describe the fundamental principles behind nucleic acid array-based assays, while focusing on their applications towards genome-wide DNA and RNA analysis. The current capabilities and limitations of these technologies will be discussed, with a focus on areas where future development will be needed for DNA chip-based assays to achieve their full potential.
Inherited factors play an important role in the predisposition, development, and progression of neuropsychiatric illnesses. In some disorders such as Huntington's disease, mutations in single genes have been clearly demonstrated to cause the disease. 1 For the neuropsychiatric illnesses accounting for the majority of clinic visits and hospital admissions, however, the molecular bases of these conditions remain poorly understood. 2, 3 Though familial clustering and high concordance rates in monozygotic twins point to hereditary factors in manic-depressive illness, obsessive-compulsive disorder, schizophrenia, alcohol addiction, and a long list of other psychiatric disorders, defining the genetic contributions to these disorders has proven to be extremely challenging, due to their complex inheritance patterns and strong environmental components. 2, 3 However there is strong impetus to resolve these issues, as a more complete understanding of the genetic and biochemical basis of the disease state may give rise to advances in diagnosis and risk prediction as well as in the development of new therapeutic agents.
Many recent advances in medical genetics have emerged from the development of new technologies which provide the tools necessary to analyze complex systems. For example, the advent of PCR has had a revolutionary impact on almost every biological discipline. With the undertaking of the Human Genome Pro- ject, increased emphasis has been placed on developing technologies to simultaneously analyze many genes at the nucleotide level in a rapid and costeffective manner. One such emerging technology involves hybridization analysis using complex arrays of nucleic acids, often termed DNA chips. Rapid progress has been made in applying this technology towards a multitude of problems that were not addressable several years ago. These range from quantitating the expression patterns of every gene in an organism to cataloging all common DNA sequence variations in the human population. We will discuss the fundamental principles of nucleic acid array-based assays while focusing on their applications towards large-scale genomic analysis as they apply towards understanding the molecular basis of human disease. Although these technologies have yet to be used to address problems directly associated with neuropsychiatry, the current applications demonstrate the potential of using DNA chip-based approaches in virtually all areas of medical genetics.
General types and manufacture of DNA chips
The term 'DNA chip' generally refers to a gridded array of nucleic acid species attached to a flat solid support, typically a glass surface, generally not larger than a microscope slide. The ordered nature of the nucleic acid arrangement on the 'chip' surface allows for massively parallel analysis of a multitude of hybridization events occurring between the components of the DNA chip and complementary nucleic acid applied in solution to the chip surface. In practice two main types of DNA chips exist which differ in the size of the nucleic acid components on the surface of the array. These types include arrays of relatively large, usually greater than 100 bp in length, and short nucleic acid segments, typically oligonucleotides up to 25 nt in length.
Microarrays of prepared larger nucleic acid segments, typically PCR products derived from cDNA libraries averaging 1 kb in length, are usually fabricated by spotting DNA of interest onto treated microscope slides. These are often coated with poly-l-lysine to promote nucleic acid attachment through a multitude of electrostatic interactions (Figure 1) . [4] [5] [6] [7] [8] However this strategy has the drawback of decreasing the accessibility of the arrayed DNA for target hybridization.
Figure 1
Methodologies for nucleic acid array fabrication. (a) cDNA microarrays are generated by printing or spotting a PCR product onto the surface of an activated glass slide. (b) High density oligonucleotide arrays can be manufactured using photolithographic processes. In step 1, 5Ј-MeNPOC protected nucleosides are tethered to a glass surface. These photolabile 5Ј-protecting groups can be selectively removed by precisely illuminating a specific section of the chip surface. The light beam is directed towards these regions through the use of a photolithographic mask set (step 2). Removal of the 5Ј-MeNPOC protecting groups results in the exposure of 5Ј-OH groups that can be coupled to activated 5Ј-MeNPOC protected nucleoside phosphoramidites applied to the chip surface (step 3). After standard capping and oxidation steps, the process may start again.
Alternatively it is possible to covalently tether aminemodified PCR products to the surface through standard coupling chemistry. 9 cDNA microarrays of greater than 2400 elements have been manufactured using these printing methodologies. 7 In like manner, oligonucleotide arrays can be manufactured by delivering presynthesized oligonucleotides to derivatized surfaces. 10, 11 In theory this approach can yield arrays of greater than 10 4 elements. 11 Microfabricated ink-jet pumps have the potential to deliver oligonucleotides to silicon wafers as well. These approaches could be potentially used in immobilizing larger pieces of double-stranded DNA as well as proteins to create complex microarrays of biomolecules. However the practical limitations of array density and reproducibility of reagent delivery remain to be formally published in the scientific literature.
Highly effective methods have been developed for manufacturing high density oligonucleotide arrays in situ on glass surfaces. Microfluidic channels and ink jet technologies enable the spatially addressed delivery of oligonucleotide synthesis reagents on surfaces. 12, 13 Although showing much promise, detailed reports of the manufacture of oligonucleotide arrays consisting of thousands of distinct species using this technology have not yet appeared in the scientific literature. Currently the most proven means of manufacturing high density oligonucleotide arrays, based upon the scientific literature as well as commercial availability, combines photolithographic techniques developed in the semi-conductor industry with massively parallel chemical synthesis protocols (Figure 1) . 14, 15 Commercially available arrays of greater than 250 000 oligonucleotides, up to 25 nt in length, have been routinely synthesized on 1.2-cm × 1.2-cm glass surfaces and the potential exists to manufacture arrays consisting of greater than 10 6 oligonucleotides. 16 Due to inefficiency in the coupling chemistry (approximately 92-94% step yields for each added nucleotide), not all oligonucleotides in the array will be full length and there will be a significant population of truncated probes on the array surface. 15 While this has not been mentioned as a problem in published reports using arrays manufactured using this technology, increasing the efficiency and reproducibility of array synthesis chemistry remains an important challenge. 16 
Mutational analysis using oligonucleotide arrays
Mutation detection plays an important role in multiple aspects of medical genetics. 17 It is used in screening for genetic components of human diseases, whether related to cancer (as is the focus of the initial DNA chip studies described herein) or psychiatric disorders, by correlating disease status with sequence variations in candidate genes that are disproportionally found in patient relative to control populations. Identification of disease-associated genes provides the basis for subsequent studies to determine phenotypes, for example clinical manifestations of psychiatric disorders, associated with sequence variations in these genes in different groups of individuals. In some cases clinical diagnostic tests could be used to screen large numbers of individuals for mutations that may cause a predisposition towards disease. A recent example is the APOE4 allele which predisposes to Alzheimer's disease. 18 This allows for the possibility of the early detection of the clinical manifestations of disease, and in some cases preventative treatment for such individuals. In other cases, knowledge of the type of sequence variation present in a gene of interest may in the future suggest the use of therapeutic regimes specifically tailored for the individual. However, mutational analysis can be a prohibitively costly and time-consuming endeavor, especially when scanning several large genes for all possible sequence variations associated with disease. Oligonucleotide array-based technologies hold the promise of providing cost-effective high-throughput mutational analysis. 19, 20 The initial step in sample preparation for DNA chipbased mutational analysis involves PCR amplification of the sequences of interest from genomic DNA, RNA, or cloned templates. In one approach single-stranded RNA target sample is prepared by in vitro transcription reactions using template generated by PCR amplification of genomic DNA, using primer pairs containing terminal T3 and T7 promoter sequences. [21] [22] [23] Afterwards, RNA targets are subject to partial random degradation to minimize inter-and intramolecular structures which interfere with hybridization to oligonucleotide probes on the array surface. 24 Targets may be labeled with fluorescent dyes by chemical or enzymatic means to enable array hybridization detection using scanning confocal microscopes equipped with CCD cameras or photomultiplier tubes. 10, [23] [24] [25] An example of an established hybridization-based mutation detection methodology is the 'dot blot' approach. Radioactively or fluorescently labeled allelespecific oligonucleotides (ASOs) are used to probe DNA target of interest spotted onto a solid support for the presence of complementary sequences, such as those corresponding to known sequence variations in a gene associated with a psychiatric disorder. Highthroughput assays have been developed to screen for well characterized mutations and sequence variations overrepresented in certain ethnic populations. 26 However, since only a limited number of these previously known variant alleles can be assayed for at one time, 27 analysis of genes with large genetic heterogeneity in the general population (likely to be the case for genes with complex clinical manifestations such as psychiatric disorders) using such a non-exhaustive analytical approach often will not be highly informative.
The limitations of the 'dot blot' approach can be addressed by inverting the hybridization format such that the oligonucleotide 'probe' is tethered to a solid support and the 'target' is present in solution. This 'reverse dot blot' format is exemplified by hybridization-based mutational analysis of the CFTR gene using high density oligonucleotide arrays. 25 Arrays of 1480 oligonucleotide probes were designed to detect 37 known CFTR mutations in both the homozygous and heterozygous states. In ten blinded samples, all sequence variants specifically assayed for were successfully detected by measuring gain of hybridization signals to redundant mutation-specific probes in test samples.
Scanning for all possible homozygous and heterozygous changes in any sequence of interest is a more technically demanding application of oligonucleotide array technology. Searching for heterozygous sequence variants is especially difficult since the presence of wild-type sequence in the sample can mask the presence of mutant alleles. Two complementary oligonucleotide array-based approaches are used to address this problem. The first involves analyzing probes complementary to a significant subset of all possible sequence changes (Figure 2 ). Relative gain of hybridization signal to any of these probes indicates the presence of sequence change in an analogous fashion to the previously described CFTR assay. The second involves measuring selective loss of hybridization signal to 'perfect match' probes complementary to wild-type sequence. 22, 23 In principle, these strategies can be applied towards the analysis of virtually any gene of interest, including those associated with psychiatric disorders.
A recent study, using oligonucleotide arrays to detect heterozygous mutations in the hereditary breast cancer BRCA1 gene, highlights the fundamental principles of both 'gain' and 'loss' of hybridization signal analysis. In this study, pairs of arrays were designed to scan the 3.43-kb BRCA1 exon 11 sequence for all possible sequence changes in the heterozygous state. 23 Each array, analyzing sense or antisense target strands, contained over 48 300 20-mer probes. Four probes per target nucleotide, substituted with one of the four nucleotides in the central position, interrogated for the presence of all possible base substitutions. In like manner, probes were designed to query for all possible single base pair insertions and (1-5)-bp target deletions. It was not feasible to interrogate for larger insertions with the gain of hybridization signal approach due to the exponential increases in the number of probes needed to represent all the possible sequence changes. Furthermore, probes whose nucleotide composition differs significantly from wild-type probe sequence frequently have idiosyncratic hybridization properties.
To overcome intrinsic limitations of gain of signal analysis, two color assays measuring BRCA1 target hybridization to wild-type 'perfect match' probes were used. In this approach, wild-type reference and RNA test target labeled with different fluors were competitively co-hybridized to the arrays in tetramethylammonium chloride buffer (used to help normalize the thermodynamic stability of AțT-and GțC-rich probetarget complexes). 23 Relative hybridization to overlapping perfect match probe sets tiled across the BRCA1 exon 11 sequence was measured. Identical reference and test sequence tracts should provide perfect match probe hybridization signal ratios (reference/test) close to one. Conversely a sequence difference between test and reference samples should produce a peak centered nearby the variation, due to a diminution of test sample hybridization ( Figure 3 ). Ideally, a maximum peak value of 2 should be expected from a heterozygous base change. This represents the hybridization of only one wild-type allele in the test sample. In practice, legitimate loss of hybridization peaks with maximum values of 1.3 can be detected over background experimental noise. Legitimate loss of hybridization signal can be differentiated from loss of signal due to isolated chip artifacts because it involves the agreement of hybridization signals derived from multiple probes. Since the gain of hybridization signal approach relies upon data generated from individual probes, mutational analysis is more robust with the loss of signal approach. Furthermore, since the loss of signal assay does not rely upon probes tailored to detect specific mutations, it is possible to scan targets for all possible sequence variations not involving repetitive sequences. This is especially important when analyzing genes with significant allelic heterogeneity in the general population, as probably will be the case in many genes associated with psychiatric disorders.
Genomic DNA samples containing fifteen distinct heterozygous BRCA1 mutations were analyzed using both gain and loss of signal criteria. 23 Fourteen of fifteen known mutations were detected with no falsely identified sequence changes. When considered individually, the loss of signal displayed increased sensi- tivity and specificity relative to the gain of signal assay. False positive signals identified by the loss of signal approach were discarded by referring to specific gain of signal probes. Confirmatory dideoxysequencing analysis of indicated sequence changes was recommended in this strategy due to the less predictable nature of the gain of signal probes as well as the absence of probes specific for all possible sequence changes.
In our laboratory, similar DNA-chip based two color mutational analyses have been performed on other large genes such as BRCA2 28 and ATM 29 (9.2 and 10.3-kb, coding sequence respectively). Figure 4a shows a superimposed image of the co-hybridization of control (labeled with a green dye) and test (labeled with a red dye) ATM DNA samples. Sequences in common to both samples produce a yellow hybridization signal while sequence differences produce green or red signals respectively. A close-up of the image (Figure 4b ) displays a red hybridization signal at one oligonucleotide probe. Further magnification (Figure 4c) shows this corresponds to the 'T' probe at position 9022 which indicates the presence of at least one 9022 T allele in the test sample. The yellow signal at the 9022 'C' probe indicates an allele common to both test and reference samples. Therefore the test sample is scored as a 9022 C/T heterozygote. This corresponds to a known ATM missense mutation which causes an arginine to cysteine amino acid substitution. 30 Minisequencing-based assays are another potentially exciting application of oligonucleotide arrays for mutation scanning. [31] [32] [33] In this approach, target hybridization to arrayed oligonucleotide probes is analyzed using primer extension reactions. The probes containing exposed 3Ј-OH groups are tethered via their 5Ј-end to the array surface. These arrayed probes serve as primers and hybridized target as template for primer extension reactions using labeled dideoxyribonucleoside triphosphates. The identity of the extended dideoxynucleotide is used to assign the target nucleotide 3Ј to the end of the probe. Heterozygous single nucleotide changes should yield two signals corresponding to the nucleotides complementary to the two alleles. Both strands need to be analyzed to determine the starting and ending points of inserted and deleted sequences; however, their exact nature cannot always be determined. One study has demonstrated the potential of the minisequencing approach as a mutational screen- ing tool by analyzing a 33-base region of the p53 gene for all possible sequence changes. 33 More work is warranted to fully characterize the strengths and potential weaknesses of this mutational analysis approach on larger genes and longer nucleotide tracts.
Gene mapping and identification
The ability of high density oligonucleotide array-based assays to identify the nature of sequence variation between individual DNA samples is useful not only for mutational analysis but also in gene mapping and association studies, which search for correlations between the presence of sequence variations and a specific clinical phenotype such as schizophrenia or bipolar disorder. 2, 3 Single nucleotide polymorphisms (SNPs) are highly abundant sequence variations present within human populations that are estimated to occur on average one every 1000 base pairs. 34, 35 Although the information content of each biallelic SNP marker is less than that of multiallelic microsatellite markers, this information can be rescued by examining moderately larger numbers of SNPs. A genetic map of 1500-3000 biallelic SNPs (with allele frequencies skewed as much as 80:20) should provide greater information content for traditional linkage studies relative to a current set of 300-400 microsatellite marker sets. 36 Even denser maps (SNP marker every 10 kb or less) will increase the efficiency and reliability of genomewide population-based linkage disequilibrium and association studies. 36 Such studies will be especially powerful in helping to identify the genetic basis of multifactorial human diseases, such as those involved in psychiatric disorders. In fact, genome-wide association studies have been recommended for defining the genetic basis of schizophrenia. 2 Oligonucleotide array technology will not only expedite the process of large-scale SNP discovery but also provide a rapid and cost-effective means of scoring these markers in different individuals. High density oligonucleotide arrays are being developed to simultaneously score over 2000 mapped SNP markers in a massively parallel format. 37 First, SNP markers are identified by large-scale screens of genomic sequence from several individuals of different ethnic backgrounds using oligonucleotide arrays. Second, individual SNP markers are cataloged and a 'master array' is designed to interrogate the sequences surrounding the SNP marker. 37 In a similar fashion to that of gain of signal mutation analysis, four oligonucleotide probes, each substituted in the central position by one of the four possible nucleotides, interrogate the SNP position of interest along with approximately 5 bp of flanking sequence on either side. Alternative tiling schemes, based upon the presence of either allele in the sample, along with sense and antisense strand hybridization increase the sensitivity and accuracy of the assay. The target is generated by amplifying short sequence tracts surrounding each SNP marker using labeled primer pairs in order to minimize target complexity. The SNP master arrays proved capable of effectively analyzing targets derived from complex multiplex PCR reactions containing dozens of primer pairs. 37 This drastically decreases the effort needed to individually genotype large numbers of markers. Hybridization data analysis in these experiments will utilize both gain and loss of signal approaches.
RNA expression analysis
Another major application of DNA chip technology, using arrays of either oligonucleotides or larger nucleic acid segments, is in simultaneously measuring relative changes in the cellular levels of many thousands of RNA species in a rapid and cost-effective manner. Current technologies typically used in RNA expression analysis, such as Northern blot and RNase protection assays, only allow the expression levels of a small number of genes to be analyzed at a given time. For neuropsychiatric disorders, DNA chip-based RNA expression analysis will be useful in two areas. First, when samples are available global mRNA expression patterns could be assayed in tissues (eg brain) from affected individuals and compared to those of unaffected individuals. Identification of differentially expressed genes between affected and unaffected populations could aid in the identification and characterization of genes associated with psychiatric diseases. A similar strategy could be applied to animal models of psychiatric diseases. Second, changes in the specific RNA expression levels from various tissue samples in treated vs untreated patients can be analyzed to help assess the mechanism, toxicity, and efficacy of drug treatment for those afflicted with psychiatric disorders. Such analysis may suggest new avenues for rational drug design as downstream targets of existing drugs, which may have serious side effects or limited efficacy, are elucidated.
cDNA microarrays have been successfully used to simultaneously monitor the expression of thousands of genes in diverse organisms including yeast, Arabidopsis thaliana, and humans. [4] [5] [6] [7] [8] [9] Targets for hybridization analysis are typically prepared by first isolating RNA of interest, often enriching for polyadenylated mRNA species. Fluorescently tagged cDNA is generated by reverse transcription using a oligo(dT) primer and dye-labeled deoxynucleoside triphosphates. Two color competitive co-hybridization analysis can be performed using targets internally labeled with different fluors. [4] [5] [6] [7] [8] [9] In these experiments, the co-hybridization patterns of the separate targets are compared and relative differences are quantitated using fluorescence microscopy ( Figure 5 ). For example, the hybridization patterns of fluorescently labeled cDNA target derived from tumorigenic and nontumorigenic (suppressed by introduction of a normal human chromosome 6), human melanoma cell lines to microarrays of 1161 partially redundant cDNA clones were compared. 5 mRNA levels for 15/870 genes were significantly diminished (Ͼ0.52-fold decrease), while those of 63/870 genes were significantly increased (Ͼ2.4-fold increase) in the nontumorogenic relative to the tumorigenic cell line.
High density oligonucleotide arrays have also been used for monitoring gene expression. Double stranded cDNA is prepared from RNA of interest using oligo(dT) primer containing a T7 RNA polymerase tail. 38, 39 cRNA target is generated by in vitro transcription reactions using dye or hapten-labeled ribonucleoside triphosphates and partially fragmented to disrupt secondary structures. The arrays typically consist of 20-50 different oligonucleotides complementary to distinct regions of each monitored gene. Since oligonucleotide arrays of greater than 250 000 different probes can be manufactured, the expression levels of over 10 000 genes can be analyzed on a single array. Oligonucleotide probes, typically 25 nt in length, are selected based on uniqueness of sequence (to minimize cross-hybridization) and empirical rules derived to predict hybridization specificity and sensitivity. 38 Since the probes are selected to possess similar hybridization properties, hybridization signal intensities normalized to signals from message of known concentration are used to predict mRNA abundance. The expression of all predicted yeast open reading frames have been examined with this technology. 39 High density arrays designed to assay the expression of over 10 000 different human genes are currently being developed by Affymetrix (Santa Clara, CA, USA).
For both array approaches, it has been estimated that mRNA species comprising 1/(300 000-500 000) of the mass of analyzed RNA can be readily detected. 9, 39 In one study monitoring the differential expression of 1000 genes in response to phorbol ester treatment in human T cells, Northern blot analysis was used for comparison to cDNA microarray analysis. In 14 distinct genes analyzed by both techniques, Northern blot analysis showed a less than two-fold difference in expression ratios and a less than five-fold difference in assessing absolute expression levels relative to cDNA microarray analysis. 9 Signal quantitation using the oligonucleotide array approach was linear over three orders of magnitude when measuring known concentrations of distinct mRNA species added to the hybridization solution. 38 The choice of using either cDNA microarrays or high density oligonucleotide arrays to monitor RNA expression is dependent upon several variables. cDNA microarrays may be used to analyze the expression of genes for which no sequence information is known by using anonymous clones from cDNA libraries. 9 This may be especially important when studying RNA expression levels in brain which expresses a large diversity of mRNA species. On the other hand, partial sequence information is needed to design oligonucleotide probes to monitor the levels of specific RNA species. 38 Nevertheless, the sequence information necessary to design oligonucleotide arrays to measure expression levels of all human open reading frames is rapidly becoming available as a consequence of the Human Genome Project. The cDNA microarray approach encounters problems measuring the expression of distinct members of gene families, as may be the case when studying neurotransmitter trans- Figure 5 Image of a cDNA microarray hybridization-based experiment for monitoring RNA expression levels. RNA expression levels of irradiated and non-irradiated lymphoblast cell lines were compared using the cDNA-based microarray shown in the upper panel. Cultures were harvested 4 h after irradiation and total RNA from each culture was reverse transcribed and tagged with fluorescent nucleotides. Red and green intensities represent the abundance of transcripts from the irradiated and control cell lines respectively. Red and green boxed spots indicate genes where a statistically significant increase or decrease of transcripts from irradiated cells is observed, respectively. The bright red (marked A) and green (marked B) spots are detectors for the p21 gene (frequently induced by DNA damage) and c-myc gene (frequently decreased in abundance when cell growth is stopped) respectively. The histogram in the lower panel shows the ratios of expression levels for all the genes in the experiment. The curve is the expected distribution of ratios, based on the ratio distributions observed for a set of 88 genes likely to be expressed at constant ratios. Ratios to the left of the green line or the right of the red line are 99% likely to represent true changes in the level of transcript between the cell samples. We thank Dr Mike Bittner at the National Human Genome Research Institute for kindly providing this image and analysis. porters, 40 due to cross-hybridization of conserved target sequences to PCR products on the array surface. In the oligonucleotide array approach, short oligonucleotide probes of unique sequence are used to minimize this problem. In addition, this approach enables the expression of distinct mRNA splice isoforms to be monitored simply by choosing short probes complementary to splice junction sequences. It is more difficult to accomplish this using the cDNA approach, due to the challenge of generating longer probes that are specific for different splice isoforms and have minimal cross-hybridization to other splice variants.
Currently the major disadvantage of both RNA expression monitoring techniques is their cost. Both the commercially available cDNA microarray (Synteni) and the high density oligonucleotide array (Affymetrix) assays currently have comparable costs (approximately $3000) for monitoring the expression levels of 6000 human genes. Analogous arrays which can monitor gene expression from model organisms such as mouse are available in both array formats as well. While high density oligonucleotide array manufacture is too capital intensive a process to commonly reproduce, cDNA microarray manufacture is more amenable towards manufacturing in a smaller laboratory setting. Custom cDNA microarrays may be printed in individual labs for several hundred dollars which makes larger scale experiments more economically feasible. Detailed instructions for the creating a complete cDNA microarray-based RNA expression monitoring system is available on the World Wide Web. 41 More affordable lower density filter arrays which interrogate the expression levels of hundreds of genes are now commercially available (from Clontech and Genome Systems among others), that can be used in expression analysis. Given the increasing number of options for use in hybridization-based RNA expression analysis, it is likely that the cost of all these systems will decrease over time.
Evolutionary sequence analysis
High density oligonucleotide arrays have proven useful for the analysis of highly related orthologous sequences. Arrays designed for mutational analysis of the human BRCA1 exon 11 sequence were used to acquire sequence information from BRCA1 orthologs found in higher primates as well as other mammals. 42 These arrays were particularly accurate in determining sequence from chimpanzee, gorilla, and orangutan orthologs, which ranged from 98.5-99.2% nucleotide identity with respect to human sequence. High density oligonucleotide arrays designed to interrogate human sequence may provide a useful tool for the large-scale determination of genomic sequence from these species. Such information could provide insights into the genetic basis for the many phenotypic differences between humans and other higher primates, such as the development of bipedal locomotion and the evolution of the human brain.
Other applications
The ability of DNA arrays to detect specific sequences in complex mixtures has been creatively used for a number of applications. For example, oligonucleotide arrays have been used to analyze the function of yeast genes. 43 A large number of deletion strains have been generated using PCR strategies that introduce short sequence tags into the disrupted gene of interest. The presence of an individual yeast strain in a complex population can be scored by analyzing total population yeast genomic DNA sequence on arrays interrogating for the presence of these unique tagged sequences.
Large numbers of yeast deletion strains can be simultaneously assayed for their ability to grow under numerous selection conditions. The cDNA microarray technology approach has also been cleverly used in genomic studies. Microarrays of clones of yeast genomic DNA were probed with fluorescently labeled target derived from specific subsets of yeast chromosomes. This provided a rapid and efficient means of physically mapping a complex population of cloned DNA. 44 Such arrays have been used in conjunction with genomic mismatch scanning (GMS) experiments to identify genomic regions that are 'identical by descent' between affected relative pairs. In a nonblinded proof of the principle experiment, a combination of GMS and microarray hybridization approaches was used to map the SUR1 gene, responsible for congenital hyperinsulinism, to a 2-MB region without conventional genotyping analysis. 45 
Conclusions
Novel applications for nucleic array hybridizationbased technologies are emerging at a swift pace and should allow a systematic attack on previously daunting questions of medical genetics, especially in neuropsychiatric research. In order for such arrays to become well proven and commonly used research tools, incremental advances towards improving the sensitivity and accuracy of gene expression monitoring, mutation analysis, and SNP discovery are necessary. Recent attempts to improve the format of array-based assays have yielded promising results. [46] [47] [48] [49] The current general accessibility and affordability of nucleic acid array-based technologies are less than optimal. However the maturation of this technology and the existence of multiple competing approaches could help resolve these issues in the near future. Perhaps the biggest challenge awaiting those utilizing DNA arraybased genomic analysis in the future is in analyzing the wealth of genetic information obtained from expression, mutation, and SNP discovery efforts. As DNA chip assays come to fruition through the use of multidisciplinary approaches, the analysis of data generated from their use will require much creative effort.
